Biotech

All Articles

Analysts explore Avidity's DMD gain, showing distinctions in records

.Avidity Biosciences satisfied capitalists with phase 1/2 data in Duchenne muscle dystrophy (DMD) Fr...

Actinogen's cortisol blocker stops working phase 2 depression study

.Actinogen Medical's cortisol blocker has actually overlooked the main endpoint of a period 2 resear...

Bivictrix decides going exclusive only way to take ADC into clinic

.Antibody-drug conjugates (ADCs) have actually gone to the center of several a billion-dollar biobuc...

TPG bests up funds to $580M for investments around life sciences

.Resource manager TPG, which has actually sustained biotechs including Sionna Therapeutics and Santa...

Merck ceases phase 3 TIGIT trial in bronchi cancer for futility

.Merck &amp Co.'s TIGIT system has gone through an additional trouble. Months after shuttering a sta...

After a hard year, Exscientia folds into Recursion

.After a year described through pipeline hairstyles, the departure of its own CEO and also layoffs, ...

Cullinan, after $25M bargain, return bispecific to Port

.Cullinan Therapy was actually blown away sufficient along with Harbour BioMed's bispecific immune r...

A nearer consider Tough Biotech's Ferocious 15

.Within this week's incident of "The Leading Line," our team are actually diving in to Fierce Biotec...

Lilly faces period 2 failure of tau-targeting med

.The confetti is still soaring coming from Eli Lilly's party commemorating the commendation of Alzhe...

Biogen CMO Maha Radhakrishnan joins Sofinnova-- Chutes &amp Ladders

.Accept to this week's Chutes &amp Ladders, our roundup of substantial leadership hirings, shootings...